What makes a quinolone a 'fluoroquinolone'?

The addition of a fluorine atom (typically at the C-6 position) to the quinolone core, which historically improved potency and broadened the antibacterial spectrum compared with the earlier non-fluorinated quinolones such as nalidixic acid.

Why are fluoroquinolones called nucleic-acid synthesis inhibitors?

Because they act on the bacterial enzymes (DNA gyrase and topoisomerase IV) that manage DNA topology during replication, blocking DNA synthesis rather than, for example, cell-wall or protein synthesis.

Fluoroquinolones and Nucleic Acid Synthesis Inhibitors

Fluoroquinolones are a class of broad-spectrum synthetic antibacterial agents that kill bacteria by interfering with the enzymes that manage DNA topology during replication. Derived from the older quinolone nalidixic acid by adding a fluorine atom and other substituents, they target bacterial type II topoisomerases — DNA gyrase and topoisomerase IV — and so belong to the broader group of nucleic-acid synthesis inhibitors. This area orients the reader to their mechanism, chemistry, safety profile, and pharmacology.

Znajdź temat z PaperMindWkrótceFind papers & topics

Tools & resources

Pobierz slajdy

Learn & explore

WideoWkrótce

Definition

Fluoroquinolones are fluorinated 4-quinolone antibacterials that inhibit bacterial DNA gyrase and topoisomerase IV, blocking DNA supercoiling and decatenation and thereby preventing replication; as such they are nucleic-acid synthesis inhibitors with concentration-dependent bactericidal activity.

Scope

The area surveys fluoroquinolones as a pharmacological class: how their core chemistry relates to antibacterial activity, how they act on bacterial topoisomerases, their characteristic adverse effects, and their pharmacokinetics and drug interactions. It is a reference-educational overview of mechanism and class behaviour, not clinical prescribing guidance.

Sub-topics

Core questions

How does the quinolone core structure determine antibacterial potency and spectrum?
Why do fluoroquinolones act on DNA gyrase and topoisomerase IV, and what distinguishes the two targets across organisms?
What class-characteristic adverse effects (tendinopathy, phototoxicity, QT effects, neuropathy) define their safety profile?
How do absorption, distribution, and cation chelation shape their pharmacokinetics and drug interactions?

Key concepts

Bacterial type II topoisomerases (DNA gyrase, topoisomerase IV)
Quinolone pharmacophore and the C-6 fluorine
Concentration-dependent bactericidal killing
Ternary drug-enzyme-DNA cleavage complex
Target-mediated resistance (gyrA/parC mutations)
Cation chelation and divalent-metal interactions
Class-effect adverse events

Mechanisms

Fluoroquinolones bind a transient enzyme-DNA complex formed by DNA gyrase or topoisomerase IV, stabilising the cleaved-DNA intermediate so that double-strand breaks accumulate and replication halts; the trapped ternary complex, rather than simple enzyme inhibition, underlies their bactericidal action (Drlica & Zhao, 1997). Gyrase is generally the primary target in Gram-negative bacteria and topoisomerase IV in many Gram-positive bacteria, and the relative affinity helps explain spectrum. Structure-activity work shows that substituents around the bicyclic quinolone core tune potency, spectrum, and pharmacokinetics, with the C-6 fluorine and C-7 ring systems being especially influential (Domagala & Hagen, 2014). Resistance arises chiefly through point mutations in the target enzymes and through reduced intracellular accumulation (Hooper, 1999).

Clinical relevance

Fluoroquinolones are among the most widely studied antibacterial classes, and understanding their mechanism and class-effect toxicities is part of pharmacology education and evidence appraisal. This overview describes how the class works and why regulators have flagged certain adverse effects; it is not individualized prescribing or treatment advice (Owens & Ambrose, 2005).

Evidence & guidelines

Mechanistic understanding rests on enzymology and microbiology reviews (Drlica & Zhao, 1997; Hooper, 1999), while safety characterization draws on pharmacovigilance and class-safety reviews (Owens & Ambrose, 2005). Regulatory agencies have issued repeated class-wide safety communications on fluoroquinolones; specific current guideline text should be consulted directly rather than summarized here.

History

The class descends from nalidixic acid, a 1960s by-product of chloroquine synthesis with modest Gram-negative activity. Adding a fluorine at C-6 and a piperazine at C-7 produced norfloxacin and then ciprofloxacin, dramatically broadening spectrum and potency; later 'respiratory' fluoroquinolones extended Gram-positive and atypical coverage. The accompanying recognition of class-characteristic toxicities reshaped how the drugs are positioned in therapy.

Key figures

Karl Drlica
David C. Hooper
John M. Domagala

Seminal works

drlica-zhao-1997
hooper-1999

Frequently asked questions

What makes a quinolone a 'fluoroquinolone'?: The addition of a fluorine atom (typically at the C-6 position) to the quinolone core, which historically improved potency and broadened the antibacterial spectrum compared with the earlier non-fluorinated quinolones such as nalidixic acid.
Why are fluoroquinolones called nucleic-acid synthesis inhibitors?: Because they act on the bacterial enzymes (DNA gyrase and topoisomerase IV) that manage DNA topology during replication, blocking DNA synthesis rather than, for example, cell-wall or protein synthesis.